Sir,
We appreciate the attention given by Drs Dutt, Salvesen, Greulich, Sellers, Beroukhim and Meyerson to our recent publication ‘The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas’ (Shoji et al, 2009). In this article, we report a 2% mutational frequency of AKT1 (E17K) among 101 endometrial carcinomas. We also described that these two AKT1 mutant tumours do not possess any mutations in PIK3CA, PTEN and K-Ras. Our report has proposed two issues to be clarified: (1) Are there any ‘oncogenic’ mutations in other AKT family members in endometrial carcinomas? (2) Are all the AKT family mutations mutually exclusive with other PI3 kinase-AKT-activating mutations?
Including the data in their earlier report, Dutt et al (2008) revealed mutations in AKT2 and AKT3, as well as in AKT1. As for AKT1 (E17K) mutations, their data and our data are compatible, showing that AKT1 mutations were detected in 2% of the endometrioid subtype in endometrial cancer. Compared with the accumulative data in AKT1 (E17K) mutations, mutations in AKT2 and AKT3 are not well characterised. Carpten et al (2007) and Kim et al (2008) reported no E17K mutations in AKT2 and AKT3 in breast, colorectal, gastric, hepatocellular, lung carcinomas and acute leukaemias. Davies et al (2008) first reported AKT3 (E17K) mutations in melanoma at 1.5% frequency. Parsons et al (2005) found two mutations of AKT2 (S302G and R371H) in 204 colorectal cancer samples, and Soung et al (2006) reported one missense mutation (A377V) and two possible splice-site mutations in intron 11 of AKT2 in gastric and lung adenocarcinoma. However, the physiological role of AKT2 mutations, including those (D399N, R368C and D32H) reported by Dutt et al (2008), has not been validated yet. In addition, the AKT3 (E438D) mutation has not been reported in any type of tumours. It is important to clarify whether these rare AKT2/3 mutations cause an oncogenic effect in cancer.
We previously reported that PIK3CA mutations frequently coexist with mutations in PTEN and/or KRAS, and suggested that the PIK3CA mutation might require another upstream input to fully activate the PI3K kinase–AKT pathway (Oda et al, 2005, 2008). Their data of coexistent mutations in AKT1 (E17K) and KRAS (G13D) suggest that the KRAS mutation alone is insufficient for a full activation of the PI3 kinase–AKT pathway. Their data are not inconsistent with the hypothesis that the AKT1 (E17K) mutation and the PIK3CA mutation are mutually exclusive. The coexistent mutations of AKT3 and PIK3CA in one sample suggest that some types of AKT mutations (non-E17K) might coexist with PIK3CA mutations to enhance the activation of the PI3 kinase–AKT pathway. Further analyses are necessary to clarify the frequency of coexistent mutations in AKT1 (E17K), AKT2/3 and other mutations.
Their current data and our data suggest that the PI3 kinase–AKT pathway is prevalently activated in endometrial cancer through various genetic alterations and their combinations. Further analyses in AKT, PIK3CA and other PI3 kinase-AKT-related genes would be helpful to comprehensively understand the mechanism of activation in this pathway and to use PI3K-targeted therapies in various types of cancer.
We thank Dr Dutt and colleagues for their recognition of our work.
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Carpten JD, Faber AL, Horn C, Donoho GP, Briggs SL, Robbins CM, Hostetter G, Boguslawski S, Moses TY, Savage S, Uhlik M, Lin A, Du J, Qian YW, Zeckner DJ, Tucker-Kellogg G, Touchman J, Patel K, Mousses S, Bittner M, Schevitz R, Lai MH, Blanchard KL, Thomas JE (2007) A transforming mutation in the pleckstrin homology domain of AKT1 in cancer. Nature 448: 439–444
Davies MA, Stemke Hale K, Tellez C, Calderone TL, Deng W, Prieto VG, Lazar AJ, Gershenwald JE, Mills GB (2008) A novel AKT3 mutation in melanoma tumours cell lines. Br J Cancer 99: 1265–1268
Dutt A, Salvesen HB, Chen TH, Ramos AH, Onofrio RC, Hatton C, Nicoletti R, Winckler W, Grewal R, Hanna M, Wyhs N, Ziaugra L, Richter DJ, Trovik J, Engelsen IB, Stefansson IM, Fennell T, Cibulskis K, Zody MC, Akslen LA, Gabriel S, Wong KK, Sellers WR, Meyerson M, Greulich H (2008) Drug-sensitive FGFR2 mutations in endometrial carcinoma. Proc Natl Acad Sci USA 105: 8713–9717
Kim MS, Jeong EG, Yoo NJ, Lee SH (2008) Mutational analysis of oncogenic AKT E17K mutation in common solid cancers acute leukaemias. Br J Cancer 98: 1533–1535
Oda K, Stokoe D, Taketani Y, McCormick F (2005) High frequency of coexistent mutations of PIK3CA PTEN genes in endometrial carcinoma. Cancer Res 65: 10669–10673
Oda K, Okada J, Timmerman L, Rodriguez Viciana P, Stokoe D, Shoji K, Taketani Y, Kuramoto H, Knight ZA, Shokat KM, McCormick F (2008) PIK3CA cooperates with other phosphatidylinositol 3′-kinase pathway mutations to effect oncogenic transformation. Cancer Res 68: 8127–8136
Parsons DW, Wang TL, Samuels Y, Bardelli A, Cummins JM, DeLong L, Silliman N, Ptak J, Szabo S, Willson JK, Markowitz S, Kinzler KW, Vogelstein B, Lengauer C, Velculescu VE (2005) Colorectal cancer: mutations in a signalling pathway. Nature 436: 792
Shoji K, Oda K, Nakagawa S, Hosokawa S, Nagae G, Uehara Y, Sone K, Miyamoto Y, Hiraike H, Hiraike-Wada O, Nei T, Kawana K, Kuramoto H, Aburatani H, Yano T, Taketani Y (2009) The oncogenic mutation in the pleckstrin homology domain of AKT1 in endometrial carcinomas. Br J Cancer 101: 145–148
Soung YH, Lee JW, Nam SW, Lee JY, Yoo NJ, Lee SH (2006) Mutational analysis of AKT1 AKT AKT3 genes in common human carcinomas. Oncology 70: 285–289
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Shoji, K., Oda, K., Nakagawa, S. et al. Reply: Somatic mutations are present in all members of the AKT family in endometrial carcinoma. Br J Cancer 101, 1220–1221 (2009). https://doi.org/10.1038/sj.bjc.6605302
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6605302